On Monday, SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)’s shares inclined 1.32% to $9.20.
SciClone Pharmaceuticals, Inc. (SCLN) stated financial results for the quarter ended June 30, 2015.
- Revenues:In the second quarter 2015, SciClone stated revenues of $37.9 million, contrast to $32.5 million for the same period in 2014.
- GAAP Diluted EPS:In the second quarter 2015, SciClone stated a GAAP diluted loss per share of $0.08, contrast to earnings per share of $0.18 for the same period in 2014.
- Non-GAAP Diluted EPS:In the second quarter 2015, SciClone stated non-GAAP diluted earnings per share of $0.26, contrast to $0.20 for the same period in 2014.
- SEC Settlement Agreement:In July 2015, SciClone reached a contract in principle with the staff of the US Securities and Exchange Commission (SEC) for a projected settlement for a range of matters, counting without admitting or denying possible violations of the Foreign Corrupt Practices Act (FCPA). The agreement, which comprises disgorgement, prejudgment interest, and penalties totaling $12.8 million, is contingent upon the execution of formal settlement documents and approval of the settlement by the SEC’s governing Commission. The Company has not yet reached a resolution of these matters with the Department of Justice (DOJ) and administration continues to work diligently to obtain closure on this matter.
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, in addition to for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems.
Fiserv Inc (NASDAQ:FISV)’s shares gained 1.52% to $88.84.
Fiserv, Inc. (FISV), a leading global provider of financial services technology solutions, recently stated financial results for the second quarter of 2015.
GAAP revenue in the second quarter was $1.30 billion contrast with $1.25 billion in the second quarter of 2014. Adjusted revenue was $1.23 billion in the second quarter contrast with $1.18 billion in the second quarter of 2014, an enhance of 4 percent. For the first six months of 2015, GAAP revenue was $2.57 billion contrast with $2.49 billion for the first six months of 2014. Adjusted revenue was $2.42 billion in the first half of 2015 contrast with $2.33 billion in the same period in 2014, an enhance of 4 percent.
GAAP earnings per share from ongoing operations in the second quarter was $0.53, which comprised of debt extinguishment and refinancing costs of $0.25 per share, contrast with $0.65 in the second quarter of 2014. GAAP earnings per share from ongoing operations for the first six months of 2015 was $1.26 contrast with $1.31 for the first six months of 2014.
Fiserv, Inc., together with its auxiliaries, provides financial services technology worldwide. The company’s Payments and Industry Products segment provides debit, credit, and prepaid card processing and services; electronic bill payment and presentment services; Internet and mobile banking software and services; person-to-person payment services; and other electronic payments software and services.
At the end of Monday’s trade, OHR Pharmaceutical Inc (NASDAQ:OHRP)‘s shares dipped -1.28% to $2.32.
Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development company, stated results for its third fiscal quarter ended June 30, 2015.
orporate Highlights for the Quarter Ended June 30, 2015, and Recent Events
- In April, presented detailed results on OHR-102 from the IMPACT study at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, Colorado
- Topically administered OHR-102 combination therapy led to improved visual function in patients with wet AMD.
- Patients with classic containing CNV demonstrated a mean gain in visual acuity at month nine of +11 letters for the OHR-102 combination arm and +5 letters with Lucentis(R) monotherapy, a clinically meaningful benefit of 6 letters. In addition, 44% of patients treated with OHR-102 combination therapy gained 3 or more lines of vision contrast to only 29% in the Lucentis monotherapy group at month 9.
- Patients with an occult CNV area less than 10mm2, regardless of classic CNV being present, treated with the combination of OHR-102 and Lucentis PRN, demonstrated a positive visual acuity benefit contrast to the Lucentis monotherapy arm which was similar to that seen in the classic containing CNV population.
- As formerly stated, the mean number of injections between the treatment arms, the primary endpoint of the study, was not meaningfully different.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
Macquarie Infrastructure Corp (NYSE:MIC), ended its Monday’s trading session with 0.28% gain, and closed at $76.57.
Macquarie Infrastructure Corporation (MIC) declared that Liam Stewart has been seconded by the Company’s manager, Macquarie Infrastructure Administration (USA), to serve as chief financial officer of MIC effective June 30, 2015. The MIC board of directors has simultaneously approved the secondment and elected Stewart chief financial officer.
Stewart succeeds Todd Weintraub who was employed by Macquarie and seconded to MIC in May of 2005. Weintraub was designated chief financial officer of the Company in November of 2008.
Stewart joined Macquarie and has worked with MIC since April of 2014 serving as asset director for MIC’s Atlantic Aviation business since that time. In addition, he has led various holding company level projects counting the build out of MIC’s Contracted Power and Energy segment.
Macquarie Infrastructure Company LLC, through its auxiliaries, owns, operates, and invests in infrastructure businesses that provide services to businesses and individuals primarily in the United States. It operates through four segments: International-Matex Tank Terminals (IMTT), Atlantic Aviation, Contracted Power and Energy (CP&E), and Hawaii Gas. The IMTT segment offers bulk liquid storage, handling, and other services for petroleum products, various chemicals, renewable fuels, and vegetable and animal oils at 10 marine terminals in the United States and 2 marine terminals in Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
